TrialSignal
Clinical trial intelligence report
Anti-BCMA CAR T-Cell Therapy for Relapsed/Refractory Immune Thrombocytopenia
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 16, 2026
NCT ID
NCT05315778
Status
UNKNOWN
Phase
Phase 2
Sponsor
The First Affiliated Hospital of Soochow University
Executive brief
Investment-Ready Snapshot
The study evaluates the efficacy and safety of Anti-BCMA CAR T-cell therapy in patients with relapsed/refractory immune thrombocytopenia (R/R ITP). Given the limited treatment options for R/R ITP, successful outcomes could position this therapy as a novel intervention in a niche market. The collaboration with Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. may enhance development capabilities and commercialization potential. However, the competitive landscape includes other emerging therapies targeting similar patient populations, necessitating a robust differentiation strategy based on clinical efficacy and safety profiles.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05315778
Indication
ITP
Modality
protein therapy
Target
BCMA (B-cell maturation antigen)
Intervention
autologous anti-BCMA chimeric antigen receptor T cells
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.